Moreover, our in silico findings predicted that both GR37 and GR41 target different epitopes on the CD19 molecule (in comparison with that targeted by the CD19-specific scFv FMC63) which can increase their clinical applicability in the cases where hematologic malignancy patients experience relapse due to the resistance to a particular CD19-redirected CAR-T therapy [57, 58]. The gene discussed is CD19; the disease is hematologic disorder.